Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Onglyza saxagliptin: Additional Phase IV data

The trial enrolled patients with Type II diabetes who had either a history of established cardiovascular disease or multiple risk factors, with or without renal impairment, to receive once-daily 2.5 or 5 mg Onglyza or placebo with or without other anti-diabetic therapies. Data were published in the New England Journal of Medicine and

Read the full 535 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers